Tests inobrodib with pomalidomide and dexamethasone in relapsed myeloma
Tests inobrodib with two other drugs in adults with returned multiple myeloma.
Plain-language title generated from the registry record
Registry title: Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Key facts
- Where
- Ann Arbor, Atlanta, Bethesda, Boston, Charlotte, Chicago, Cleveland, Hackensack, Iowa City, Jacksonville, Milwaukee, New Brunswick, Omaha, Philadelphia, Phoenix, Rochester, San Francisco, Seattle, St Louis, Tampa, and Winston-Salem, United StatesSee the 21 sites
- Phase
- Phase 2
Where in United States
- University of MichiganAnn Arbor, United StatesTaking people
- Winship Cancer InstituteAtlanta, United StatesTaking people
- American Oncology Partners, PABethesda, United StatesTaking people
- Dana-Farber Cancer InstituteBoston, United StatesTaking people
- Levine Cancer InstituteCharlotte, United StatesTaking people
- University of Chicago Medical CenterChicago, United StatesTaking people
- Cleveland ClinicCleveland, United StatesTaking people
- John Theurer Cancer Center at Hackensack University Medical CenterHackensack, United StatesTaking people
- University of Iowa Health CareIowa City, United StatesTaking people
- Mayo Clinic FloridaJacksonville, United StatesTaking people
- Froedtert Hospital & the Medical College of WisconsinMilwaukee, United StatesTaking people
- Rutgers Cancer Institute of New JerseyNew Brunswick, United StatesTaking people
- University of Nebraska Medical CenterOmaha, United StatesTaking people
- University of Pennsylvania/Abramson Cancer CenterPhiladelphia, United StatesTaking people
- Mayo Clinic - ArizonaPhoenix, United StatesTaking people
- Mayo ClinicRochester, United StatesTaking people
- University of California San FranciscoSan Francisco, United StatesTaking people
- Fred Hutchinson Cancer CenterSeattle, United StatesTaking people
- Washington University School of MedicineSt Louis, United StatesTaking people
- H Lee Moffitt Cancer Center & Research InstituteTampa, United StatesTaking people
- Wake Forest University Health SciencesWinston-Salem, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- CellCentric Ltd.
- Trial code
- NCT07096778
- Record updated
- 21 September 2026
- Original description
The purpose of this study is to learn more about the anti-cancer activity of inobrodib, when given in combination with pomalidomide and dexamethasone, in patients with multiple myeloma that has come back following treatment and which no longer responds to available therapies. The study treatment will not be compared to any other treatment and patients will know what treatment they are receiving. This study will also further explore the side effects of inobrodib in combination with these other medicines.Read full original descriptionShow less
A Phase II, Open-Label, Multicenter Study of Inobrodib in Combination With Pomalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to learn more about the anti-cancer activity of inobrodib, when given in combination with pomalidomide and dexamethasone, in patients with multiple myeloma that has come back following treatment and which no longer responds to available therapies. The study treatment will not be compared to any other treatment and patients will know what treatment they are receiving. This study will also further explore the side effects of inobrodib in combination with these other medicines.
Inclusion: Male or female ≥18 years of age; Prior diagnosis of MM as defined according to IMWG criteria and relapsed or refractory to the last line of therapy; Eastern Co-operative Oncology Group (ECOG) performance status of 0 to 2; Adequate hematological, renal and hepatic function; Willingness to use highly effective contraceptive measures (if sexually active) with all sexual partners.
Exclusion: Use of any investigational agent, chemotherapy, immunotherapy or anticancer agent from a previous clinical study within 14 days or 5 half-lives of first dose of study treatment, whichever is shortest; Prior treatment with p300/CBP bromodomain inhibitors; Known or suspected severe allergies to any active or inactive ingredients in the study medications (inobrodib, pomalidomide, dexamethasone) or any prior immunomodulatory drug (lenalidomide, thalidomide); Treatment with medicines or herbal supplements or foods (e.g. strong CYP3A4 inducers or inhibitors) that would interfere with treatment; Major surgery within 4 weeks of the first dose of study treatment; Live vaccine within 4 weeks of study treatment; Active malignancies (progressing or requiring change in treatment) in the last 24 months other than multiple myeloma; Any illness or medical history that would impact safety or compliance with study requirements or impact ability to interpret study data; Active or unresolved adverse events; Female patients who are pregnant or breast-feeding at any time during the study.